Treatment of Classical Kaposi Sarcoma With Nicotine Dermal Patch: A Phase II Trial
- Evaluate the toxicity and efficacy of transdermal nicotine applied to lesions in
patients with classic Kaposi's Sarcoma.
OUTLINE: This is a double-blind, placebo-controlled study.
Patients apply a nicotine dermal patch to a selected lesion and a placebo patch to the other
lesion, replacing the same type of fresh patch every other day, during the first 2 weeks,
increasing the nicotine dose in week 3 and again in week 5 for a total of 15 weeks in the
absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 24 patients will be accrued for this study.
Masking: Double-Blind, Primary Purpose: Treatment
Tumor response at weeks 9 and 15
James J. Goedert, MD
National Cancer Institute (NCI)
United States: Federal Government
|Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support||Bethesda, Maryland 20892-1182|